Nama's AI scorecard currently rates Takeda Pharmaceutical Hold (4.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is TAK's P/E ratio?

Takeda Pharmaceutical trades at a trailing price-to-earnings ratio of 42.0.

What is the TAK price target?

The median analyst price target from 3 analysts is $22.01, with a range of $20.92 – $25.91.

Is TAK Shariah compliant?

Nama's AAOIFI-style screen reads Takeda Pharmaceutical as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does TAK pay a dividend?

Yes — Takeda Pharmaceutical's dividend yield is 3.0%.

Nama Insights

Takeda Pharmaceutical (TAK)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Takeda Pharmaceutical (TAK) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $67.16B, a trailing price-to-earnings ratio of 42.0 and a free-cash-flow yield of 6.0%. Over the most recent reported fiscal year, revenue declined 1.7% and free cash flow per share fell 5.7%. Nama's AI scorecard rates it Hold, 4.6 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 4.6/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +34.7% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-3.3%

How far the last close sits under the highest price of the past five years.

Market cap	$67.16B
Trailing P/E	42.0
Price / book	0.7
Price / sales	2.3
FCF yield	6.0%
Dividend yield	3.0%
Gross margin	65.8%
Operating margin	14.9%
Net margin	0.9%
Revenue growth (YoY)	-1.7%
Revenue growth (3-yr annual)	+3.8%
EPS growth (YoY)	—
FCF/share growth (YoY)	-5.7%
Beta	0.1
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

TAK earnings

Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q1 2024	Jul 27, 2023	$0.18	$0.12	+54.5%	—
Q2 2023	Oct 27, 2022	$0.13	$0.43	-70.3%	—
Q1 2023	Jul 28, 2022	$0.22	$0.38	-42.7%	—
Q2 2022	Oct 28, 2021	-$0.03	$0.61	-105.3%	—

TAK analyst price target

Median target $22.01 from 3 analysts, ranging $20.92 – $25.91.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3
RDY	Dr. Reddy's Laboratories	$12.43B	20.4

Explore live TAK data on Nama Insights →

Recent Congressional trades

Takeda Pharmaceutical trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Virginia Foxx	House	Sell	$15,001 - $50,000	Sep 5, 2023
Daniel Goldman	House	Sell	$15,001 - $50,000	Aug 13, 2023

TAK FAQ

Is TAK a buy?: Nama's AI scorecard currently rates Takeda Pharmaceutical Hold (4.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TAK's P/E ratio?: Takeda Pharmaceutical trades at a trailing price-to-earnings ratio of 42.0.
What is the TAK price target?: The median analyst price target from 3 analysts is $22.01, with a range of $20.92 – $25.91.
Is TAK Shariah compliant?: Nama's AAOIFI-style screen reads Takeda Pharmaceutical as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does TAK pay a dividend?: Yes — Takeda Pharmaceutical's dividend yield is 3.0%.